Effect of Gemfibrozil, Rifampicin, or Probenecid on the Pharmacokinetics of the SGLT2 Inhibitor Empagliflozin in Healthy Volunteers - Macha, Sreeraj; Koenen, Rüdiger; Sennewald, Regina; Schöne, Katja; Hummel, Noemi; Riedmaier, Stephan; Woerle, Hans J.; Salsali, Afshin; Broedl, Uli C. (Clinical therapeutics, 2014)
Keywords: Adolescent; Adult; Benzhydryl Compounds - pharmacokinetics; Biological and medical sciences; Cross-Over Studies; Drug dosages; Drug Interactions; Drug therapy; Drug Therapy, Combination; empagliflozin; Female; Gemfibrozil - pharmacokinetics; Glucose; Glucosides - pharmacokinetics; Haplotypes; Humans; Internal Medicine; Male; Medical Education; Medical sciences; Metabolites; Middle Aged; organic anion transporters; Pharmacology. Drug treatments; Probenecid - pharmacokinetics; Rifampin - pharmacokinetics; Sodium-Glucose Transporter 2 - antagonists & inhibitors; Studies; Substance abuse treatment; uridine diphosphate glucuronosyltransferase; empagliflozin; drug interactions; uridine diphosphate glucuronosyltransferase; organic anion transporters; Glycosyltransferases; Uricosuric agent; SGLT2 inhibitor; Rifampicin; Organic anion transporter; Antituberculous agent; Drug interaction; Protein synthesis inhibitor; Probenecid; Human; Empagliflozin; Healthy subject; UDP-glucuronosyltransferase; Fibrate derivatives; Enzyme; Transferases; Antibiotic; Sulfonamides; Gemfibrozil; Hexosyltransferases; Antibacterial agent; Pharmacokinetics; Antilipemic agent